Literature DB >> 2242543

Increased endothelin in experimental heart failure.

K B Margulies1, F L Hildebrand, A Lerman, M A Perrella, J C Burnett.   

Abstract

Recent studies demonstrate that endothelin, a potent endogenous vasoconstrictor peptide, circulates in plasma of normal animals and humans. However, the role of this peptide in pathophysiological states remains unclear. The present study was designed to test the hypothesis that circulating endothelin concentrations are increased in experimental congestive heart failure (CHF), a pathophysiological state characterized by activation of vasoconstrictor mechanisms. In anesthetized dogs with CHF produced by 8 days of rapid ventricular pacing (n = 28), circulating plasma endothelin was increased compared with values for normal controls (n = 28; 20.4 +/- 1.4 versus 9.7 +/- 0.9 pg/ml, respectively; p less than 0.0001). A plasma endothelin level of more than 14.0 was a sensitive and specific indicator of significant CHF. Moreover, within the group with experimental CHF, right atrial pressure and pulmonary capillary wedge pressure correlated independently with circulating endothelin levels. Based on recent studies demonstrating the physiological actions of twofold increases in circulating endothelin, as observed in the present study, a possible role for endothelin in the pathophysiology of CHF is advanced.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242543     DOI: 10.1161/01.cir.82.6.2226

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  30 in total

1.  The role of endothelin in the pathogenesis of heart failure.

Authors:  John R Teerlink
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 2.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  Endothelins: pathophysiology and treatment implications in chronic heart failure.

Authors:  John R Teerlink
Journal:  Curr Heart Fail Rep       Date:  2005-12

4.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

Review 5.  Coronary endothelial function in health and disease.

Authors:  J C Burnett
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 6.  Cardioprotective signaling by endothelin.

Authors:  Anita Schorlemmer; Michelle L Matter; Ralph V Shohet
Journal:  Trends Cardiovasc Med       Date:  2008-10       Impact factor: 6.677

7.  Protective effects of endothelin-1 on acute pancreatitis in rats.

Authors:  M Kogire; K Inoue; S Higashide; K Takaori; Y Echigo; Y J Gu; S Sumi; K Uchida; M Imamura
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

8.  Rapid increase in plasma endothelin concentrations during percutaneous balloon dilatation of the mitral valve in patients with mitral stenosis.

Authors:  O Kinoshita; H Yoshimi; S Nagata; F Ishikura; K Kimura; T Yamabe; K Takagaki; K Miyatake; T Omae
Journal:  Br Heart J       Date:  1993-04

Review 9.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

10.  Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.

Authors:  Se Min Ryu; Hark Jei Kim; Kyu Ran Cho; Won-Min Jo
Journal:  J Korean Med Sci       Date:  2009-09-23       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.